Holen Sie sich die Stockscreener-App
5.47
0.37%
0.02
Handel nachbörslich:
5.47
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BHC?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$5.45
Offen:
$5.48
24-Stunden-Volumen:
1.61M
Relative Volume:
0.87
Marktkapitalisierung:
$2.04B
Einnahmen:
$10.53B
Nettoeinkommen (Verlust:
$-1.23B
KGV:
-1.6852
EPS:
-3.246
Netto-Cashflow:
$949.99M
1W Leistung:
+0.92%
1M Leistung:
-3.70%
6M Leistung:
-9.29%
1J Leistung:
+21.56%
1-Tages-Spanne:
$5.38
$5.565
1-Wochen-Bereich:
$5.24
$5.61
52-Wochen-Spanne:
$4.41
$8.685
Bausch Health Companies Inc Stock (BHC) Company Profile
Firmenname
Bausch Health Companies Inc
Sektor
Telefon
514-744-6792
Adresse
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Compare BHC vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
5.47 | 2.04B | 10.53B | -1.23B | 949.99M | -3.246 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2024-08-02 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2024-07-10 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-20 | Hochstufung | Jefferies | Hold → Buy |
| 2023-06-16 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2022-07-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-07-29 | Herabstufung | Truist | Buy → Hold |
| 2022-07-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-06-13 | Fortgesetzt | JP Morgan | Overweight |
| 2021-03-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-02-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-01-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-09-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-24 | Eingeleitet | Citigroup | Buy |
| 2020-04-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-01-22 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2019-12-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-02 | Eingeleitet | Goldman | Neutral |
| 2019-10-25 | Eingeleitet | Cowen | Outperform |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-15 | Hochstufung | TD Securities | Hold → Buy |
| 2019-07-19 | Eingeleitet | Wolfe Research | Outperform |
| 2019-06-11 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-01-02 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-11-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-13 | Hochstufung | Piper Jaffray | Underweight → Neutral |
Alle ansehen
Bausch Health Companies Inc Aktie (BHC) Neueste Nachrichten
Bausch Health Cos (BHC) Stock Price, News & Analysis $BHC - MarketBeat
BHC Stock Price, Quote & Chart | BAUSCH HEALTH COS INC (NYSE:BHC) - ChartMill
Bausch Health (NYSE: BHC) director sells 24,456 shares under plan - Stock Titan
New Bausch Health (BHC) director Eiry Roberts added as insider on Form 3 - Stock Titan
BHC: Sustained growth, China expansion, and BLCO monetization drive strategic priorities - TradingView
Bausch Health shareholders elect board members and approve auditor at annual meeting By Investing.com - Investing.com South Africa
Bausch Health shareholders elect board members and approve auditor at annual meeting - Investing.com
Shareholders of Bausch Health (NYSE: BHC) approve directors, pay and PwC - Stock Titan
Eiry Roberts to chair Bausch Health science and technology committee - Stock Titan
[144] Bausch Health Companies Inc. SEC Filing - Stock Titan
Bausch + Lomb launches PreserVision AREDS3 eye vitamins in U.S. By Investing.com - Investing.com Australia
Bausch + Lomb launches PreserVision AREDS3 eye vitamins in U.S. - Investing.com UK
Cannabis Pharmaceuticals Business Research Report 2026: An - GlobeNewswire
Cannabis Pharmaceuticals Business Research Report 2026: An $111.1 Billion Market by 2032 from $4.7 Billion in 2025 Featuring AbbVie, Aphria, Aurora Cannabis, Bausch Health, and Canopy Growth - Yahoo Finance
Bausch Health rises on Q1 double beat, 2026 guidance - MSN
Bausch Health Companies (BHC) price target decreased by 10.52% to 6.72 - MSN
Dry Eye Products Market Will Generate Booming Growth - openPR.com
Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference - The Globe and Mail
Hear Bausch Health chiefs in live RBC healthcare chat May 20 - Stock Titan
Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference - 富途牛牛
Bausch Health's Q1 Total Prescriptions Hurt by Exit From Federal Drug Pricing Programs, RBC Says - Moomoo
Bausch Health Cos (BHC) Earnings Date and Reports 2026 $BHC - MarketBeat
Bausch Health to redeem ~$602M of outstanding notes due 2026 - MSN
Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe – Company Announcement - Financial Times
Bausch Health: Strong Margins, Weak Volumes, Equity Story Hinges On Deleveraging - Seeking Alpha
How many employees work at Solta Medical? - Revelio Labs
Bausch Health (BHC) Q1 2026 Earnings Transcript - AOL.com
Bausch Health Companies Inc. (NYSE:BHC) Q1 2026 Earnings Call Transcript - Insider Monkey
MSN Money - MSN
Bausch Health Companies Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:BHC) 2026-05-04 - Seeking Alpha
Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight - GlobeNewswire Inc.
Bausch Health reaffirms 2026 guidance of $5.250B-$5.400B revenue and $2.875B-$2.950B adjusted EBITDA as tariffs are built in - MSN
Bausch Health Companies Q1 2026 Results: Revenue Up 12%, EPS Beats ForecastsNews and Statistics - IndexBox
symbol__ Stock Quote Price and Forecast - CNN
Why Bausch Health Companies was crawling higher this week - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Teladoc (TDOC), Bausch Health Companies (BHC) and AbbVie (ABBV) - The Globe and Mail
Why Bausch Health Companies Was Crawling Higher This Week - The Motley Fool
Bausch Health Companies Inc. Q1 2026 Quarterly Report Highlights Financial Performance, Risks, and Forward-Looking Statements - Minichart
Bausch Health Cos (NYSE:BHC) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Bausch Health Rises on Strong 1Q Segment Growth, Revenue Beat - Moomoo
BHC Q1 Earnings Miss Estimates, Sales Grow on Salix & Solta Strength - The Globe and Mail
RBC Keeps Sector Perform Rating, US$9.00 Price Target, on Bausch Health After Strong Q1 - marketscreener.com
RBC Capital Maintains Bausch Health(BHC.US) With Hold Rating, Maintains Target Price $9 - Moomoo
Bausch Health Companies Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Bausch Health Companies Inc. 1Q 2026: Revenue $2.52B, Net income ($1.42B), EPS ($3.82) — 10-Q Summary - TradingView
Bausch Health Cos Q1 Earnings Call Highlights - MarketBeat
Bausch Health (BHC) Lags Q1 Earnings Estimates - Yahoo Finance
Compared to Estimates, Bausch (BHC) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Finanzdaten der Bausch Health Companies Inc-Aktie (BHC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.92%
4.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):